Diploma (LON:DPLM) had its price target boosted by Barclays from GBX 1,225 ($16.01) to GBX 1,300 ($16.99) in a research report report published on Tuesday, ThisIsMoney.Co.Uk reports. They currently have an equal weight rating on the stock.
DPLM has been the subject of several other reports. Peel Hunt reaffirmed an add rating on shares of Diploma in a research report on Wednesday, January 16th. HSBC started coverage on Diploma in a research report on Tuesday, February 12th. They issued a hold rating and a GBX 1,325 ($17.31) target price for the company. Berenberg Bank dropped their target price on Diploma from GBX 1,435 ($18.75) to GBX 1,350 ($17.64) and set a hold rating for the company in a research report on Tuesday, January 29th. Finally, Numis Securities lifted their target price on Diploma from GBX 1,420 ($18.55) to GBX 1,475 ($19.27) and gave the company a hold rating in a research report on Monday, May 13th. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of GBX 1,412.86 ($18.46).
LON DPLM opened at GBX 1,509 ($19.72) on Tuesday. The stock has a market capitalization of $1.71 billion and a price-to-earnings ratio of 31.70. Diploma has a 1-year low of GBX 1,144 ($14.95) and a 1-year high of GBX 1,654 ($21.61).
In related news, insider Johnny Thomson acquired 22,000 shares of the stock in a transaction dated Monday, February 25th. The stock was acquired at an average cost of GBX 1,349 ($17.63) per share, with a total value of £296,780 ($387,795.64).
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in North America, Europe, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies consumables and instruments for the diagnostic testing of blood, tissue, and other samples in hospital pathology and life sciences laboratories; electrosurgery and minimally invasive surgery equipment and consumables for use in hospital operating rooms; and surgical medical devices, and related consumables and services to GI endoscopy suites in hospitals and private clinics.
Featured Article: SEC Filing
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.